N/A N=91 Microvascular Blood Flow in Sickle Cell Anemia
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=147 A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain
Osteoarthritis
Primary: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.13; -1.43 score on a scale
N/A N=59 Suicide Prevention in Rural Veterans During High-risk Care Transition Scenarios
Suicidal and Self-injurious Behavior
Primary: The Beck Scale for Suicidal Ideation (BSS) — -2.5; -6.0; -2.6; -5.7 score on a scale
Phase 3 N=20 Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
Type2 Diabetes
Primary: Change in Percentage of HbA1c From Baseline to 3 Months — 1.6 change in percentage of HbA1c
N/A N=320 Evaluating an eHealth Solution for Screening in Pediatric Care
Pain · Stress Disorders, Post-Traumatic
Primary: Validity of eScreen Pain Measure as Predictor of Child's Clinically Significant Pain Severity at 6 Weeks
N/A N=74 Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV
HIV-1-infection · Hypertension
Primary: Proportion of Eligible Participants Who Agree to Participate — 74 Participants
N/A N=52 Menthol and Mint Experimental Tobacco Marketplace (ETM) Study
Cigarette Smoking · Vaping
Primary: Total Amount of Combusted Tobacco Purchased — 990.6 mg
Phase 2 N=65 Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Relapsed or Refractory Peripheral T-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 56.3; 7.1; 40.0; 0.0 percentage of participants — p=0.000
Phase 3 N=318 A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Cachexia; Cancer · Non Small Cell Lung Cancer
Primary: Mean Change From Baseline in Body Weight Over 12 Weeks — 1.938; 0.594 Change from baseline in body weight (kg) — p=<0.0001
Phase 3 N=400 Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
N/A N=148 Effectiveness of Telepsychiatry With Randomized Waitlist Control Utilizing Patient Reported Outcome Measures
PROMs · Waitlist · Telemedicine
Primary: Measurement of Symptomatology of Patients on Waitlist Via Patient Health Questionnaire (PHQ-9) — 13.41; 13.48; 13.60; 13.00 score on a scale — p=<0.05
Phase 1 N=31 Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of a Lipid- Based Lubricating Eye Drop
Visual Acuity
Primary: Visual Acuity (logMAR) at 3 Minutes Post Instillation — 0.09; 0.08 LogMAR
N/A N=991 ACTION PAC: Adolescents Committed to Improvement of Nutrition & Physical Activity
Overweight · Obesity
Primary: Number and Proportion of Participants With Baseline BMI <85th Percentile Who Developed Overweight or Obesity by the End of the Study — 22; 12 Participants
Phase 3 N=318 A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Cachexia; Cancer · Non Small Cell Lung Cancer
Primary: Mean Change From Baseline in Body Weight Over 12 Weeks — 1.822; 0.538 kg — p=<0.0001
N/A N=185 Motivational Interviewing and Culture for Urban Native American Youth (MICUNAY)
Alcohol Use · Marijuana Use
Primary: Number of Participants Who Used Alcohol From Baseline to 6 Months — 22; 33 Participants